Nils Hansen

1.0k total citations
24 papers, 584 citations indexed

About

Nils Hansen is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Nils Hansen has authored 24 papers receiving a total of 584 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 12 papers in Genetics and 8 papers in Oncology. Recurrent topics in Nils Hansen's work include Chronic Myeloid Leukemia Treatments (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers) and Eosinophilic Disorders and Syndromes (8 papers). Nils Hansen is often cited by papers focused on Chronic Myeloid Leukemia Treatments (14 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers) and Eosinophilic Disorders and Syndromes (8 papers). Nils Hansen collaborates with scholars based in Sweden, Switzerland and United States. Nils Hansen's co-authors include Thoas Fioretos, Marianne Rissler, Marcus Järås, Helena Ågerstam, Johan Richter, Maria Askmyr, Carin Lassen, Gunnar Juliusson, Tor Olofsson and Ole Weis Bjerrum and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Blood.

In The Last Decade

Nils Hansen

24 papers receiving 579 citations

Peers

Nils Hansen

HEMAT

IMMUN

GENET

ONCOL

Camelia Iancu‐Rubin United States

Danielle Cain United States

Doan Le Canada

F-X Mahon France

Parva Bhatt United States

Brittany A. Woods United States

Michela Rondoni Italy

Karen Lambie Canada

Mayuka Nakatake Japan

M Teramura Japan

Camelia Iancu‐Rubin United States

Nils Hansen

342 ×1.0

HEMAT

76 ×0.4

IMMUN

281 ×1.5

GENET

292 ×1.6

149 ×1.0

ONCOL

Citations per year, relative to Nils Hansen Nils Hansen (= 1×) peers Camelia Iancu‐Rubin

Countries citing papers authored by Nils Hansen

Since Specialization

Citations

This map shows the geographic impact of Nils Hansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nils Hansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nils Hansen more than expected).

Fields of papers citing papers by Nils Hansen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nils Hansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nils Hansen. The network helps show where Nils Hansen may publish in the future.

Co-authorship network of co-authors of Nils Hansen

This figure shows the co-authorship network connecting the top 25 collaborators of Nils Hansen. A scholar is included among the top collaborators of Nils Hansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nils Hansen. Nils Hansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rai, Shivam, Yang Zhang, Nils Hansen, et al.. (2024). IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells. Blood Advances. 8(5). 1234–1249. 15 indexed citations

Hansen, Nils, Alexandre Guy, Shivam Rai, et al.. (2024). The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN. Blood Advances. 8(9). 2312–2325. 8 indexed citations

Paz, Damien Luque, Nils Hansen, Lucia Kubovčáková, et al.. (2024). Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F–positive myeloproliferative neoplasms. Blood. 143(24). 2490–2503. 3 indexed citations

Fields, James K., Elin Jaensson Gyllenbäck, Sara Rattik, et al.. (2024). Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling. Cell Reports. 43(5). 114099–114099. 7 indexed citations

Hansen, Nils, et al.. (2024). Blocking IL1RAP on cancer-associated fibroblasts in pancreatic ductal adenocarcinoma suppresses IL-1-induced neutrophil recruitment. Journal for ImmunoTherapy of Cancer. 12(12). e009523–e009523. 6 indexed citations

Rai, Shivam, Nils Hansen, Damien Luque Paz, et al.. (2022). Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm. Nature Communications. 13(1). 5346–5346. 37 indexed citations

Paz, Damien Luque, Nils Hansen, Shivam Rai, et al.. (2022). Combination of 5-Azacytidine and Pegifna Is Able to Overcome Resistance in JAK2-V617F Positive MPN with Loss of Dnmt3a. Blood. 140(Supplement 1). 3876–3877. 5 indexed citations

Rao, Tata Nageswara, Nils Hansen, Damien Luque Paz, et al.. (2021). JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Blood. 137(16). 2139–2151. 31 indexed citations

Hansen, Nils, et al.. (2020). Loss of Dnmt3a Confers Resistance to Pegifnα in JAK2-V617F Mouse Model. Blood. 136(Supplement 1). 8–9. 1 indexed citations

10.

Rai, Shivam, et al.. (2019). IL-1β Secreted from Mutant Cells Carrying JAK2-V617Ffavors Early Clonal Expansion and Promotes MPN Disease Initiation and Progression. Blood. 134(Supplement_1). 307–307. 13 indexed citations

11.

Palffy, Sofia von, Niklas Landberg, Carl Sandén, et al.. (2019). A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells. Haematologica. 105(8). 2095–2104. 9 indexed citations

12.

Askmyr, Maria, Sofia von Palffy, Nils Hansen, et al.. (2017). Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells. PLoS ONE. 12(10). e0186035–e0186035. 4 indexed citations

13.

Magnusson, Linda, Nils Hansen, Jenny Nilsson, et al.. (2017). Loss of the tumour suppressor gene AIP mediates the browning of human brown fat tumours. The Journal of Pathology. 243(2). 160–164. 7 indexed citations

14.

Ågerstam, Helena, Nils Hansen, Sofia von Palffy, et al.. (2016). IL1RAP antibodies block IL-1–induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood. 128(23). 2683–2693. 70 indexed citations

15.

Ågerstam, Helena, Christine Karlsson, Nils Hansen, et al.. (2015). Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proceedings of the National Academy of Sciences. 112(34). 10786–10791. 86 indexed citations

16.

Askmyr, Maria, Helena Ågerstam, Henrik Lilljebjörn, et al.. (2014). Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells. Blood Cancer Journal. 4(12). e269–e269. 11 indexed citations

17.

Askmyr, Maria, Helena Ågerstam, Nils Hansen, et al.. (2013). Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 121(18). 3709–3713. 91 indexed citations

18.

Hansen, Nils, Helena Ågerstam, Martin Wahlestedt, et al.. (2012). SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function. Leukemia. 27(1). 130–135. 10 indexed citations

19.

Järås, Marcus, Nils Hansen, Helena Ågerstam, et al.. (2010). Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proceedings of the National Academy of Sciences. 107(37). 16280–16285. 133 indexed citations

20.

Wolf, Matthias, Nils Hansen, & H. Greten. (1994). Interleukin 1β, tumor necrosis factor-α and interleukin 6 decrease nuclear thyroid hormone receptor capacity in a liver cell line. European Journal of Endocrinology. 131(3). 307–312. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact